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Introduction
Malignant pleural effusions (MPEs) represent a 
significant health burden and are an important 
cause of cancer-related mortality and morbidity. 
They are common, affecting 15% of all patients 
with cancer [Clive et  al. 2016a]. There are 
150,000 new diagnoses of MPE in the USA each 
year [American Thoracic Society, 2000], and 
50,000 in the UK [Rahman et  al. 2010a]. It 
is anticipated that incidence will increase as 
survival rates for cancer improve and the popu-
lation ages.
The majority of patients with MPE are sympto-
matic, with breathlessness the predominant 
symptom [Roberts et al. 2010]. Importantly the 
severity of symptoms does not always correlate to 
the size of the effusion. Other factors, including 
the speed of fluid accumulation and the presence 
of any respiratory comorbidities, contribute to the 
degree of breathlessness experienced. Patients 
with MPE may also report chest pain, a dry cough 
or indigestion and early satiety due to pressure 
effects on the stomach.
MPE is a marker of poor prognosis, and median 
survival varies from 3 months to 12 months 
depending on underlying tumour type [Lui et al. 
2016a; Roberts et al. 2010]. Since management of 
MPE is invariably palliative, interventions should 
focus on relieving symptoms whilst minimalizing 
hospitalization [Thomas et al. 2014]. It is worth 
noting that some patients do not experience 
any improvement in symptoms following fluid 
removal, and for these patients a conservative 
approach is acceptable.
The heterogeneity of MPE with regards to fluid 
production and response to treatment means that 
management should be personalized [Bhatnagar 
and Maskell, 2014]. Clinicians should take into 
account patient factors, such as individual pref-
erence and the presence of comorbidities, MPE 
factors, including the rate of recurrence, presence 
of septations or trapped lung, and tumour char-
acteristics, for example, cancer type, disease 
stage and predicted prognosis [Lui et al. 2016a]. 
Diagnostic and therapeutic interventions under-
taken during the patient’s initial investigations 
can help to determine whether symptoms improve 
after aspiration of fluid, and consequently can 
inform future management.
Investigations
Imaging
A posterior-anterior chest radiograph is the first-
line investigation for suspected MPE. A fluid 
level will be visible if over 200 ml of pleural 
fluid is present [Hooper et al. 2010]. Other radio-
logical signs of MPE include lobulated pleural 
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thickening, crowding of ribs, elevation of the 
hemidiaphragm and mediastinal shift, either 
towards the affected side due to volume loss from 
an obstructing tumour, or away from the lesion 
due to pressure effects from fluid [Heffner and 
Klein, 2008]. A massive effusion, with mediasti-
nal shift and diaphragmatic inversion, is associ-
ated with an increased probability of malignancy 
[Heffner and Klein, 2008].
Thoracic ultrasound (TUS) is useful to confirm 
the presence of pleural fluid and to differentiate 
between pleural fluid, pleural thickening and con-
solidation [Porcel and Light, 2013]. It can also 
suggest a malignant aetiology with certain fea-
tures (e.g. presence of pleural thickening > 1 cm, 
diaphragmatic nodularity or thickening > 7 mm, 
visceral pleural thickening and pleural nodularity/
irregularity) highly suggestive of malignancy 
[Porcel and Light, 2013]. TUS has a sensitivity of 
73% and specificity of 100% in identifying malig-
nancy and is more sensitive than computed 
tomography (CT) scans in demonstrating visceral 
pleural disease and diaphragmatic nodularity 
[Qureshi et al. 2009]. TUS also has a role in MPE 
management; its use alongside thoracentesis is 
associated with a 16% reduction in pneumotho-
rax and 39% reduction in haemorrhage [Patel 
et al. 2012].
Contrast-enhanced CT of the thorax is under-
taken in most patients with suspected MPE, as it 
is considered the gold standard of imaging in 
pleural malignancy. There are four main features 
on CT that are useful in differentiating malignant 
from benign disease [Leung et al. 1990]: (a) cir-
cumferential pleural thickening (specificity 100%, 
sensitivity 41%); (b) nodular pleural thickening 
(specificity 94%, sensitivity 51%); (c) parietal 
pleural thickening greater than 1 cm (specificity 
94%, sensitivity 36%); (d) mediastinal pleural 
involvement (specificity 88%, sensitivity 56%).
In general, CT features have high specificity but 
poor sensitivity for differentiating malignant from 
benign disease. In addition CT cannot reliably 
differentiate malignant pleural mesothelioma 
from pleural metastases [Leung et al. 1990].
Metabolic imaging using 18-fluorodeoxyglucose 
(FDG) positron emission tomography (PET) 
scanning is often used to stage primary lung can-
cer and other malignancies, however, its use in 
malignant pleural disease is not well defined. A 
meta-analysis of 14 studies examining the use of 
FDG PET found a sensitivity of 81% and speci-
ficity of 74% for pleural malignancy [Porcel et al. 
2015]. False negatives can occur in the presence 
of early or indolent disease, and false positives are 
possible in the context of inflammatory pleuritis, 
rheumatoid disease and previous pleurodesis. For 
this reason PET-CT is not used in routine diag-
nostic practice.
PET-CT may have a role in determining the opti-
mal sites for image-guided biopsy by identifying the 
area of highest metabolic activity. This hypothesis 
is currently under investigation in the TARGET 
trial (www.isrctn.com ISRCTN14024829), a 
multicentre, parallel group randomized control 
trial comparing PET-CT-guided biopsy with 
CT-guided biopsy in patients who have had pre-
vious negative biopsies.
Magnetic resonance imaging (MRI) can be used 
to evaluate malignant pleural disease. It provides 
better imaging of soft tissue than CT, can detect 
invasion into the chest wall and diaphragm, and 
has higher sensitivity for small effusions [Lorigan 
and Libshitz, 1989]. It has been shown to have 
higher inter-observer agreement in assessing pleu-
ral thickening, pleural effusion and extra pleural 
fat when compared with CT [Weber et al. 2004]. 
However, it is not as effective as CT for imaging 
lung parenchyma.
MRI can also provide functional information via 
the use of diffusion-weighted imaging or dynamic 
contrast enhancement. Combining this informa-
tion with standard imaging provides sensitivity 
and specificity rates of over 90% for differentiat-
ing malignant from benign pleural disease 
[Coolen et al. 2012]. However, uncertainty over 
the optimal protocol for MRI scanning alongside 
limited access in some centres means that MRI is 
not currently part of the standard investigatory 
pathway for MPE.
Pathological diagnosis
Pleural fluid sampling and cytological examina-
tion should be undertaken in all patients with a 
suspected MPE, and will provide a diagnosis in 
up to 60% of patients [Hooper et  al. 2010]. 
Certain tumour types, for example, mesotheli-
oma, sarcoma and squamous cell carcinoma have 
a much lower diagnostic sensitivity [Porcel and 
Light, 2013].
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In terms of the optimum volume of pleural fluid to 
maximize the likelihood of achieving a cytological 
diagnosis, 60 ml appears to be superior to 10 ml 
[Swiderek et  al. 2010]. However, another study 
found no statistically meaningful difference in the 
detection rate of malignant cells between 25 ml, 
50 ml and 150 ml samples (82%, 89% and 93%, 
respectively) [Khosla et  al. 2016]. The British 
Thoracic Society (BTS) guidelines advise that 
20–40 ml should be enough, unless more fluid is 
being taken off for therapeutic purposes [Hooper 
et al. 2010]. Since patients often undergo a thera-
peutic aspiration, with up to 1.5 L removed at the 
same time, larger samples may be sent for cytol-
ogy, but the diagnostic benefit of this is unclear.
There does not appear to be any cumulative 
diagnostic benefit from sending repeat samples 
for cytology if the initial sample was negative 
[Jenkinson and Murphy, 2007]. However, if 
suspicious cells are seen on the original aspirate, 
but were insufficient to provide a definitive diag-
nosis, a repeat, large-volume sample should be 
considered [Hooper et al. 2010]. If cytology does 
not yield the diagnosis, then histological diagnosis 
should be obtained via pleural biopsy. Historically 
percutaneous biopsies were performed blind, 
using a closed (Abrams) needle. However, the 
low sensitivity (57%) and high complication rate 
of this procedure has led to a decrease in its use 
[Bibby and Maskell, 2016; Tomlinson and Sahn, 
1987]. Percutaneous biopsies are now usually 
undertaken under image-guidance, using CT or 
TUS. This allows the focal area of abnormal 
pleura to be targeted under direct vision, with 
consequent higher diagnostic sensitivity and 
lower complication rates [Metintas et  al. 2010]. 
The superiority of CT-guided biopsy over the 
Abrams technique has been demonstrated in a 
randomized controlled trial, which revealed a 
sensitivity of 87% and specificity of 100% for the 
former method [Maskell et  al. 2003]. TUS-
guided pleural biopsies have a similar diagnostic 
yield to CT-guided biopsy and offer the addi-
tional benefit of no ionizing radiation [Qureshi 
and Gleeson, 2006; Sconfienza et al. 2013]. TUS-
guided pleural biopsies can be undertaken by 
respiratory physicians with a 94% diagnostic 
yield [Hallifax et al. 2014; Metintas et al. 2012]
Percutaneous biopsies are not possible in all 
patients with MPE, for instance if there is mini-
mal pleural thickening or disease is poorly acces-
sible due to the presence of other thoracic organs. 
In these patients, thoracoscopy is the preferred 
method for obtaining biopsies. Thoracoscopy can 
be undertaken under local anaesthetic (LAT) as a 
physician-operated procedure, or as video-
assisted thoracoscopy (VATS) performed by 
thoracic surgeons under general anaesthetic. 
Thoracoscopy allows direct visualization of the 
pleural surface and targeted biopsies of areas of 
disease. In addition, because pleural effusions are 
drained to dryness during thoracoscopy, the pro-
cedure offers therapeutic benefit as well as diag-
nostic information. Furthermore, if the pleura 
appears to be obviously infiltrated with malignant 
disease, and the lung is not trapped, pleurodesis 
can be undertaken, thus providing a definitive 
fluid management option at the same time.
LAT is a safe option with low mortality (0.3%) 
and major complications rates (1.8%) [Rahman 
et al. 2010a]. It has a diagnostic sensitivity of over 
90%, which is comparable to image-guided per-
cutaneous biopsy [Metintas et al. 2010].
In order to be suitable for LAT patients need to 
be able to lie in the lateral decubitus position for 
at least 30 min and to maintain reasonable oxy-
genation with conscious sedation. The effusion 
must be of sufficient size to allow the introducer 
port to be safely inserted. In patients with small 
effusions a pneumothorax can be induced with a 
Boutin needle immediately prior to thoracoscopy. 
A case series has demonstrated success rates of 
87% with this method [Corcoran et  al. 2015]. 
Patients with a tethered lung or heavily loculated 
effusions may not be suitable for LAT as the lung 
will not collapse away from the chest wall once 
the introducer port is inserted. These patients 
should be considered for a surgical VATS instead.
The diagnostic sensitivity of VATS is similar to 
LAT, at 95%, although no trial has directly com-
pared the two methods [Hooper et al. 2010]. As 
well as being suitable for patients with complex 
effusions, VATS also offers the potential for ther-
apeutic procedures, such as lung resection or 
tumour debulking, to be performed during the 
same procedure. Complications rates from a ret-
rospective audit of 86 patients undergoing VATS 
in the UK demonstrated no mortalities and a 
1.2% major complication rate [Medford et  al. 
2008]. However, due to the invasive nature of 
VATS and the need for general anaesthetic it is 
unsuitable for frail patients and those with certain 
comorbidities.
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Tumour markers
Various biomarkers have been proposed as 
noninvasive tests to help distinguish between 
benign and malignant pleural disease, and to 
give information on prognosis or treatment out-
comes [Psallidas et  al. 2016]. Multiple serum 
and pleural biomarkers such as mesothelin, 
osteopontin and fibulin-3 have been investi-
gated in MPE [Creaney et al. 2014; Pass et al. 
2005, 2012; Porcel, 2013; Porcel et al. 2004]. 
In general these biomarkers have demonstrated 
poor specificity and sensitivity and results have 
not been validated in subsequent studies 
[Psallidas et al. 2016; Sriram et al. 2011]. The 
use of established biomarkers, including carci-
noembryonic antigen and cancer antigens 
(CAs) 15-3 and 125, has limited diagnostic 
value in determining the aetiology of MPE 
[Porcel et al. 2004]
The most promising biomarker to date is meso-
thelin, a cell-surface glycoprotein that is overex-
pressed in mesothelioma [Chang et  al. 1992]. 
Mesothelin can be measured in both pleural fluid 
and serum, with similar diagnostic performances 
[Cui et al. 2014]. A meta-analysis of 4491 indi-
vidual patients with mesothelioma reported 
serum mesothelin had a sensitivity of 32% with a 
specificity of 95% [Hollevoet et  al. 2012]. 
Consequently a high pleural mesothelin serum 
level should prompt further investigations, but a 
negative test is of limited value. Mesothelin may 
be more useful in monitoring mesothelioma dis-
ease progression and response to treatment rather 
than as a diagnostic tool, but the assay is not 
widely available outside the research setting and 
there are limited data in this area.
Management
The management of MPE should include 
ongoing monitoring and symptomatic treatment 
with oxygen and opioids as required. In terms 
of interventions for MPE, the options include 
recurrent therapeutic thoracentesis, chest drain-
age and pleurodesis, insertion of an indwelling 
pleural catheter (IPC) or surgical intervention. 
Management should be personalized, and deci-
sions made based on clinical factors and individ-
ual patient preference.
Clinical factors that influence management 
include the predicted rate of pleural effusion 
recurrence, based on underlying tumour type and 
rapidity of re-accumulation after previous thera-
peutic interventions. The patient’s prognosis 
should also be considered. This may be influ-
enced by performance status [Burrows et  al. 
2000], tumour characteristics [Heffner et  al. 
2000], extent of disease [Wu et al. 2013], comor-
bidities and effusion biochemistry [Bielsa et  al. 
2008; Heffner et al. 2000; Kao et al. 2010]. The 
LENT score can be used to predict survival in 
patients presenting with a first episode of MPE 
[Clive et al. 2014]. It is summarized in Table 1, 
and can be used to stratify patients into low-, 
moderate- or high-risk groups. Median survival of 
patients with a high-risk LENT score was 44 
days, and 6-month survival was just 3% [Clive 
et al. 2014].
Other clinical factors that may influence MPE 
management include response to previous thera-
peutic aspirations, the presence of trapped lung 
or septated effusion and whether any oncological 
treatment is planned.
Therapeutic thoracentesis
Most patients will undergo therapeutic thora-
centesis at some point in their clinical pathway. 
This can provide useful information as to 
whether they derive symptomatic benefit from 
the removal of pleural fluid. This is important, 
as breathlessness may be multifactorial in people 
with MPE, and other pathologies such as bron-
chial obstruction, carcinomatous lymphangitis, 
pulmonary embolism or chronic obstructive 
pulmonary disease may co-exist. If a patient 
does not experience an improvement in breath-
lessness following a therapeutic aspiration, then 
a conservative ‘watch and wait’ policy might be 
appropriate.
Unfortunately most MPEs will recur after initial 
therapeutic aspiration, and a definitive procedure 
to control the fluid is usually required [Fysh et al. 
2015]. Undertaking repeated therapeutic thora-
centesis will expose the patient to discomfort and 
an increased risk of complications with each 
repeated procedure. Consequently this approach 
is not suitable for most patients. However, if the 
patient has a limited life expectancy, a slowly re-
accumulating effusion or does not wish to have a 
more invasive procedure, then repeated thoracen-
tesis may be an option.
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Chest drainage and pleurodesis
One method of achieving definitive control of 
MPE is complete chest drainage followed by 
chemical pleurodesis. The aim of pleurodesis is 
to induce pleural inflammation and subsequent 
adhesion of the visceral and parietal pleura, 
thus preventing fluid re-accumulation. This 
can be achieved by instilling a sclerosing agent 
via a chest drain (slurry) or by insufflation dur-
ing medical thoracoscopy (poudrage). Various 
agents have been evaluated, including antibiot-
ics (tetracycline, doxycycline, bleomycin), bac-
terial agents (Corynebacterium parvum, OK432) 
and irritants (talc). A recent Cochrane review 
of pleurodesis agents reported significant clini-
cal and statistical heterogeneity in trials of 
pleurodesis agents, but concluded that talc was 
one of the most effective interventions [Clive 
et al. 2016a].
The success rates of talc pleurodesis are reported 
as 60–75%, whether delivered via a chest drain or 
at thoracoscopy [Lui et al. 2016a]. The TIME-1 
trial suggested that wide-bore drains may be 
superior to small bore in achieving pleurodesis 
[Rahman et  al. 2015]. However, smaller chest 
tubes (12F) are more comfortable for patients 
[Rahman et  al. 2010b, 2015]. In the authors’ 
opinion, further data are required before recom-
mending using large-bore chest tubes for all 
patients. Our unit currently avoids using chest 
tubes less than 12 F and ensures these are both 
sutured in well and flushed regularly, ensuring 
patency is maintained. Rotation of the patient to 
maximize talc distribution has been advocated in 
the past, however, subsequent studies using 
radio-labelled talc have shown that rotation does 
not affect dispersal, and so it is no longer per-
formed [Dryzer et al. 1993; Mager et al. 2002]
Table 1. The LENT prognostic score calculation.
Variable Score
L (LDH in pleural 
fluid level)  < 1500 0
 > 1500 1
E (ECOG PS)
 0 0
 1 1
 3 2
 3–4 3
N (NLR)
 < 9 0
 > 9 1
T (Tumour type)
 Lowest risk tumour types 0
  Mesothelioma  
  Haematological malignancy  
 Moderate risk tumour types 1
  Breast cancer  
  Gynaecological cancer  
  Renal cell carcinoma  
 Highest risk tumour types 2
  Lung cancer  
  Other tumour types  
Risk categories Total score  
Low risk 0–1  
Moderate risk 2–4  
High risk 5–7  
Reproduced with permission from Clive et al. [2014]. ECOG PS, Eastern Cooperative Oncology Group performance score; 
LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio.
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Chest drainage and pleurodesis requires an inpa-
tient hospital stay of between 4 days and 7 days 
[Davies et al. 2012]. This may not be appropriate 
for patients with a limited life expectancy, who wish 
to spend as much time at home as possible. In addi-
tion many patients will experience pain, a fever or 
both after pleurodesis [Rahman et al. 2015]. These 
factors should be discussed with the patient when 
management decisions are being made.
Patients with trapped lung (Figure 1) or multiple 
pleural septations (Figure 2) are unlikely to 
achieve successful pleurodesis. With trapped 
lung, there is little or no pleural apposition, 
and therefore pleurodesis will be futile. An IPC 
should be offered preferentially in these people 
[Bhatnagar et al. 2016]. Heavily septated pleural 
effusions are unlikely to drain fully, and conse-
quently pleurodesis will be impaired. There were 
encouraging results initially from an observational 
trial investigating the use of fibrinolytics to dis-
solve septations in loculated MPEs [Thomas et al. 
2015]. However, a subsequent randomized con-
trol trial demonstrated that intrapleural urokinase 
does not improve dyspnoea or pleurodesis suc-
cess compared with placebo in patients with non-
draining MPEs, and therefore urokinase has no 
routine role in managing this subgroup of patients 
with MPE [Mishra et al. 2016].
Insertion of an indwelling pleural catheter
Insertion of a tunnelled IPC to allow ambulatory 
fluid drainage is another definitive method for 
managing MPE. IPC insertion can be performed 
as a day case under LAT. Drainages are under-
taken at home using sterile vacuum bottles by dis-
trict nurses or family members. The TIME 2 
study showed that IPC insertion was equally 
effective at relieving dyspnoea as chest drainage 
and talc slurry [Davies et  al. 2012]. The 
Australasian Malignant Pleural Effusion 
(AMPLE) trial replicated this result, and showed 
that patients managed with IPCs require signifi-
cantly fewer days in hospital [Lee et  al. 2016]. 
This makes IPC insertion a very attractive option 
for patients who wish to avoid a hospital stay, and 
it is important to solicit individual patient’s opin-
ions on this when deciding on MPE management 
[Maskell, 2012].
IPCs can be used in patients who have previously 
failed pleurodesis, or who are not suitable for 
pleurodesis due to trapped lung or heavily locu-
lated fluid. Interestingly, in patients whose lungs 
are not trapped, spontaneous pleurodesis has 
been reported in 45% of patients with IPCs [Van 
Meter et al. 2011]. If pleurodesis occurs, the IPC 
can be removed.
Complications of IPC insertion include infection, 
which is usually quoted as a rate of 4–5% [Fysh 
et al. 2013]. IPC-related infections appear to have 
a low overall mortality (0.29%), and can usually 
be treated with oral antibiotics, without the need 
for IPC removal [Fysh et al. 2013]. The risk of 
infection does not seem to be higher if chemo-
therapy is given [Fysh et al. 2013; Hak et al. 2016; 
Mekhaiel et  al. 2013], however it does increase 
over time.
Figure 1. Pleural effusion with trapped lung.
Figure 2. Septated pleural effusion.
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Another potential complication of IPC insertion 
is the development of catheter tract metastases 
(CTM). These present as a painful subcutane-
ous mass near the IPC insertion site or tract. 
The average incidence is below 5%, but may be 
influenced by tumour type and duration of IPC 
placement [Lui et  al. 2016b]. Patients with 
CTM can be treated with analgesia and external 
beam radiotherapy, without the need for IPC 
removal [Lui et al. 2016b]. The use of prophy-
lactic radiotherapy to prevent symptomatic 
CTM developing was recently shown not to be 
beneficial, and consequently should not be rou-
tinely performed [Clive et al. 2016b].
The increasing expertise in IPC usage has allowed 
novel uses and applications to be investigated. 
Talc has been instilled via IPCs in case studies 
[Tremblay et  al. 2007], and is being investi-
gated in a multicentre randomized control trial 
[Bhatnagar et al. 2015] (IPC PLUS www.isrctn.
com ISRCTN 73255764). IPCs also offer the 
opportunity to deliver therapies directly into the 
pleural space, an approach that is particularly 
attractive for targeted biological agents and 
immunotherapy [Islam and Takita, 2012; 
Sterman et al. 2007, 2010]. The opportunity to 
obtain multiple samples of pleural fluid from 
IPCs is an exciting prospect and may lead to 
greater understanding of the pathophysiology of 
MPE, and the potential to monitor physiological 
responses to treatments.
Surgery
Surgery has a limited role in the management of 
MPE, and benefits are often outweighed by peri-
operative mortality and reduced quality of life 
[Rintoul et al. 2014; Roberts et al. 2010]. A small 
case series reporting VATS partial pleurectomy in 
patients with MPE secondary to mesothelioma 
reported high rates of pleural fluid control [Waller 
et al. 1995]. However, a subsequent randomized 
trial comparing VATS partial pleurectomy with 
chest drainage and talc pleurodesis reported no 
difference in pleurodesis rates between the groups 
at 3 months and 12 months [Rintoul et al. 2014]. 
In addition there was no difference in survival 
between the groups, and there were significantly 
more complications in the surgical group [Rintoul 
et  al. 2014]. The authors conclude that VATS 
pleurectomy cannot be recommended in this con-
text. The 2010 BTS pleural guidelines reiterate 
this, advocating IPC insertion or chest drainage 
with chemical pleurodesis preferentially [Roberts 
et al. 2010]. At present, patients with MPE should 
only be considered for surgery in the context of a 
clinical trial, and only once patients have been fully 
informed about alternative options and the relative 
advantages and disadvantages of each method.
Conclusion
MPEs are of source of significant morbidity in 
patients who have a limited life expectancy. 
Investigations should focus on achieving a diag-
nosis via the least invasive method, in a timely 
fashion. Procedures undertaken for investigative 
purposes can also help to determine future man-
agement decisions (e.g. response to therapeutic 
thoracentesis) and some diagnostic procedures 
offer simultaneous therapeutic opportunities (e.g. 
thoracoscopy). In the past decade, a number of 
well-designed randomized trials have provided a 
robust evidence base for the investigation and 
management of MPE, and there is a range of 
treatment options that can be offered to people 
with MPE.
MPE is a heterogeneous condition, with multiple 
underlying aetiologies, variable prognosis and 
unpredictable responses to treatment. Conse-
quently each patient requires a personalized man-
agement approach in which the pros and cons of 
each therapeutic option are considered and dis-
cussed. Patient preference should be prioritized.
Further trials are underway that will hopefully 
inform and enhance MPE management in the 
future. Studies aiming to predict more accurately 
symptomatic response and individual prognosis 
will enable a more personalized approach in the 
next few years.
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